Urban Supreme System

Although the current revenue of Yadai Group is still a little behind that of Lanxiangya Group.

But I believe that with this gap, Yadai Group can surpass it soon.

Because snow cream and moisturizing cream are still on the rise, their sales will continue to increase.

Compared with Lanxiangya Group's products, they have now reached a bottleneck, and it is already very difficult to maintain the current sales volume.

Under the dual impact of snow cream and moisturizing cream, Lanxiangya Group has been hit the hardest this year, and its revenue this year will inevitably decrease significantly.

Due to the ebb and flow of one another, it is a certainty that Yadai Group's revenue will surpass that of Lanxiangya Group.

Even as long as Yade Group maintains sales of five million bottles in the coming period, its annual revenue can exceed that of Lanxiangya Group.

As for pure profit, it is even more incomparable.

According to professional estimates, Yadai Group's net profit this year is at least more than 300 billion yuan, and may even hit the 500 billion yuan mark.

As long as the sales volume of Snow Skin Cream and Moisturizing Cream maintains the current level, such performance can definitely be easily achieved.

Although Lanxiangya Group is the world's largest cosmetics company, its net profit last year was only 50 billion yuan. The gap with Yadai Group is self-evident.

Therefore, Yadai Group has now completely defeated Lanxiangya Group in terms of net profit.

As long as it operates reasonably for a period of time, Yadai Group can completely replace Lanxiangya Group and become the world's number one brand of cosmetics.

Judging from the current situation, this is not a dream, but an absolutely achievable goal.

For Yadai Group, it is now in an invincible state in the shopping mall, with no competitors that can pose a threat.

This makes Su Zhe very satisfied. It seems that it is easy for Yadai Group to become a huge cosmetics empire.

After reading the sales statistics of Yadai Group. He then browsed the production and sales situation of Changhua Pharmaceutical.

This month, Changhua Pharmaceutical's production and sales have also undergone great changes.

Now the daily output of Thawing Spirit has increased to 23 million tablets.

And blue elixir, refreshing pills. And the daily sales volume of Membrane has increased to 27 million pills.

Compared with last month, the daily output of each drug has increased by 5 million pills.

The daily output of Joint Spirit has increased to 38 million tablets, which is 6 million more than last month's daily output.

The reason why. The production plan of Changhua Pharmaceutical will increase so much because Li Changhua of Changhua Pharmaceutical has negotiated with agents in three countries and signed a final agency agreement. Therefore, the production demand for the drug has also increased significantly. .

Only by increasing the production plan to this level can the current demand be maintained. Changhua Pharmaceutical's current sales volume is basically maintained at this level.

The current output of the five drugs has basically exhausted Changhua Pharmaceutical's production capacity, and a new production line has been installed. Otherwise, we really wouldn’t be able to produce so many drugs.

Moreover, the experiments on the three drug formulas that Su Zhe handed over to Changhua Pharmaceutical last time are going very smoothly, and they are not far away from being put on the market for sale.

Therefore, Changhua Pharmaceutical's current production capacity is obviously unable to meet demand and is at a very tight level.

But fortunately, I believe this situation will pass soon.

Because Li Changhua has already identified a new acquisition target, and the production capacity and scale of this acquisition target are basically similar to those of the Qinhai Pharmaceutical Group he previously acquired. The same goes for the acquisition money required.

Now Li Changhua has negotiated with the person in charge of the other party locally, and it will soon become an industry under the name of Changhua Pharmaceutical.

By then, Changhua Pharmaceutical's production capacity will be greatly relieved. It can also meet the production capacity required for the launch of new drugs.

Changhua Pharmaceutical's current daily revenue is not much weaker than that of Yadai Group. Its single-day revenue is close to 1.4 billion yuan, and its net profit is also 540 million yuan.

This is because Su Zhe emphasizes small profits but quick turnover, and does not want patients to bear too heavy a burden. If he increases the ex-factory price tenfold, the current sales volume will not be greatly affected. In any case, the revenue and profit will reach more than ten times, far surpassing the Yadai Group.

But as a result, many poor families will not be able to afford such medical expenses and will be tortured by the disease.

Su Zhe didn't want to see this happen, so he priced all medicines at a relatively low level so that most people could afford the medicines and treatment.

Although it is impossible for him to do charity entirely, if he can make less profit and benefit more people, then he is still very willing to do so.

After all, medicines are necessities, while cosmetics are not. Their importance is not the same, and the two cannot be compared.

Therefore, Changhua Pharmaceutical's revenue and profits are now lower than those of Yadai Group.

Otherwise, if Su Zhe is willing, he can even make Changhua Pharmaceutical's revenue and profit several times that of Yadai Group in a short period of time.

The agents of Changhua Pharmaceutical are also willing to do this. Although the purchase price will increase, their final profits will also be higher.

However, even at the current price, Changhua Pharmaceutical's revenue and profits are still the envy of many pharmaceutical companies.

Because based on the current revenue and net profit of Changhua Pharmaceutical, its total revenue in a year can reach more than 500 billion yuan, and its net profit in a year is close to 200 billion yuan.

This is also due to the impact of production restrictions. Currently, Changhua Pharmaceutical’s drugs cannot be sold all over the world.

Otherwise, Changhua Pharmaceutical's revenue and net profit could increase several times.

In fact, most of Changhua Pharmaceutical's profits are contributed by foreign markets. Because domestic selling prices are low, profits are also low, while selling prices in foreign markets have increased by 50%.

Therefore, the net profit brought by foreign markets is eighteen times that of the domestic market.

Based on Su Zhe's shares in Yadai Group and Changhua Pharmaceutical, his daily net income has reached more than 1.2 billion yuan, and his annual income is more than 400 billion yuan. Such a rate of making money can be regarded as unprecedented. No one comes.

And this does not include the payment for the therapeutic potions used by Changhua Pharmaceutical and Yadai Group.

Now that the sales of Changhua Pharmaceutical and Yadai Group are better, the more therapeutic potions are needed, and the income this brings to Su Zhe is also very considerable.

Estimated based on the current consumption rate, there is an annual income of more than 300 billion yuan.

The cost for Su Zhe to refine the healing potion is very low, and the Chinese medicinal materials required are not much, so the net profit is also very high.

As a result, his annual net income is close to 800 billion yuan, of course, before paying taxes.

It’s not that I don’t know, it’s just that I was shocked. To be continued. Search "Lanse Book Bar" in your browser to read new chapters.

... ()